Key facts
- Endovascular Engineering’s last known valuation is $215.0M (Apr 2026).
- It has raised $141.0M; the latest was Later Stage VC ($80.0M) in Apr 2026.
- Notable investors include Norwest, S3 Ventures, Innovation Partnerships, Gilde Healthcare, Panakes Partners — 12 tracked in total.
- Status: Privately Held (backing).
Leadership
- Daniel RoseChief Executive Officer
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for Endovascular Engineering
- ·The full record, as it builds
Funding rounds
No funding rounds for Endovascular Engineering are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Endovascular Engineering
Developer of a minimally invasive thrombectomy system designed to remove pulmonary embolisms efficiently while minimizing patient risk. The company offers a small-profile catheter that combines a self-expanding funnel for wide distal clot engagement, dual-action technology that simultaneously agitates and aspirates clots, and integrated navigation controls that allow physicians to maneuver safely through complex vascular pathways, providing precise, controlled, and efficient clot removal during a single procedure, enabling interventional physicians to achieve effective large-bore clot engagement and safe, single-pass procedures through complex vascular anatomies.
- Sector
- Healthcare
- HQ
- Menlo Park, CA, United States
- Founded
- 2019
- Employees
- 40
- Website
- endovascularengineering.com/
- Ownership
- Privately Held (backing)
Endovascular Engineering doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Endovascular Engineering shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Endovascular Engineering in its N-PORT filings yet. We sweep new filings monthly.